Efficacy and safety of idelalisib for the treatment of indolent B-cell malignancies

Expert Opinion on Pharmacotherapy
Piotr Smolewski, Dominika Rydygier

Abstract

The outcome of patients with lymphoid malignancies has markedly improved in recent years due to the implementation of new therapeutic options. Chronic lymphocytic leukemia (CLL) and indolent B-cell non-Hodgkin lymphomas (NHL) are characterized by the activation of the phosphatidylinositol 3-kinase (PI3 K) pathway via B-cell receptor signaling. The PI3 K delta (PI3 Kδ) p110δ isoform inhibitor, idelalisib, showed high anti-tumor activity in this group of tumors. It was the first agent from a new class of isoform-specific inhibitors to receive regulatory approvals for the treatment of refractory/relapsed CLL, as well as small lymphocytic lymphoma and follicular lymphoma. In this paper, the authors provide a comprehensive overview of the activity and safety profile of idelalisib and other, newly developed PI3 K inhibitors in patients with indolent B-cell malignancies. Idelalisib is a very potent anti-lymphoma agent in CLL and other NHL. However, there are some limitations of its broad clinical use according to some important side effects observed during treatment. Consequently, the development of new PI3 K inhibitors, which will be highly active and possess better safety profiles are warranted.

References

Apr 2, 2003·Nature Reviews. Immunology·Klaus Okkenhaug, Bart Vanhaesebroeck
Mar 17, 2004·Cancer Treatment Reviews·Juan Angel Fresno VaraManuel González-Barón
Jul 16, 2004·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Al B BensonScott Wadler
Apr 10, 2010·Nature Reviews. Molecular Cell Biology·Bart VanhaesebroeckBenoit Bilanges
Dec 23, 2011·Molecular Cancer Therapeutics·Sauveur-Michel MairaCharles F Voliva
Jan 24, 2014·The New England Journal of Medicine·Richard R FurmanSusan M O'Brien
Jan 24, 2014·The New England Journal of Medicine·Ajay K GopalGilles A Salles
Jan 29, 2014·Clinical Cancer Research : an Official Journal of the American Association for Cancer Research·Cristina SauraJose Baselga
Mar 14, 2014·The New England Journal of Medicine·David A Fruman, Lewis C Cantley
Feb 3, 2015·Therapeutic Advances in Hematology·Valentín Ortiz-MaldonadoJulio Delgado
Feb 6, 2015·Clinical Cancer Research : an Official Journal of the American Association for Cancer Research·Geoffrey I ShapiroJosep Tabernero
Mar 3, 2015·Leukemia & Lymphoma·Steven E CoutréAndrew D Zelenetz
Aug 6, 2015·Clinical Pharmacokinetics·Srinivasan RamanathanBrian P Kearney
Oct 2, 2015·The American Journal of Surgical Pathology·Christine Y LouieTeri A Longacre
Oct 9, 2015·The American Journal of Surgical Pathology·Anna-Sophie WeidnerRhonda K Yantiss
Jan 21, 2016·Clinical Cancer Research : an Official Journal of the American Association for Cancer Research·Saoirse O DollyJohann S de Bono
Mar 10, 2016·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Thomas PowlesRobert J Motzer
Jun 3, 2016·Blood·Chan Yoon Cheah, Nathan H Fowler
Mar 11, 2017·European Journal of Cancer : Official Journal for European Organization for Research and Treatment of Cancer (EORTC) [and] European Association for Cancer Research (EACR)·Christophe MassardKarim Fizazi
Jun 22, 2017·Annals of Oncology : Official Journal of the European Society for Medical Oncology·M DreylingP L Zinzani
Sep 14, 2017·Critical Care : the Official Journal of the Critical Care Forum·Davide ChiumelloJean-Louis Vincent
Oct 5, 2017·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Martin DreylingPier Luigi Zinzani

❮ Previous
Next ❯

Citations

Feb 11, 2021·Cancers·Cèlia Dobaño-LópezPatricia Pérez-Galán

❮ Previous
Next ❯

Related Concepts

Related Feeds

AKT Pathway

This feed focuses on the AKT serine/threonine kinase, which is an important signaling pathway involved in processes such as glucose metabolism and cell survival.

B-Cell Leukemia (Keystone)

B-cell leukemia includes various types of lymphoid leukemia that affect B cells. Here is the latest research on B-cell leukemia.

Blood And Marrow Transplantation

The use of hematopoietic stem cell transplantation or blood and marrow transplantation (bmt) is on the increase worldwide. BMT is used to replace damaged or destroyed bone marrow with healthy bone marrow stem cells. Here is the latest research on bone and marrow transplantation.

B-Cell Lymphoma

B-cell lymphomas include lymphomas that affect B cells. This subtype of cancer accounts for over 80% of non-Hodgkin lymphomas in the US. Here is the latest research.

Related Papers

American Journal of Health-system Pharmacy : AJHP : Official Journal of the American Society of Health-System Pharmacists
Bryan DoAmber Rexwinkle
© 2021 Meta ULC. All rights reserved